[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pleural-effusion-malignant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pleural-effusion-malignant":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,75,106,130,162,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100627006","phase-1-fast-tils-to-treat-metastatic-pleural-effusions-from-epithelial-or-mesothelial-primary-tumors-100627006",false,"NCT07443020","Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors: A Phase I Trial (FAST TILS 2)","RIOT 4B","Inclusion Criteria:\n\n1. Patients with symptomatic, biopsy-proven malignant to the pleura, or mesothelioma with pleural effusions. Patients must have received and be refractory to available standard of care (SOC) therapy specific to their cancer type and must have exhausted or failed available standard of care with clinical benefit.\n2. Patients will be ≥ 18 and \\\u003C 80 years of age.\n3. Female patients of childbearing potential must have a negative urine or serum pregnancy test and if sexually active must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), an injectable contraceptive (such as Depo-Provera), or an oral contraceptive. Active contraception should continue for at least 12 months after ACT administration.\n\n   Male participants must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the preparative regimen.\n4. Cardiac ejection fraction ≥ 0.45 by MUGA or echocardiography.\n5. No requirement for supplemental oxygen and no dyspnea immediately after effusion drainage.\n6. ECOG Performance Status 0 or 1.\n7. Patients must have an expected survival \\> 12 weeks.\n8. Patients must be able to comprehend the risks and methods used in this clinical trial and independently consent to participate.\n9. Patients must consent to collection of demographic and clinical data.\n\nExclusion Criteria:\n\n1. Infection with HIV and active viral replication. Patients with an undetectable viral load on Anti-retroviral Therapy (ART) can be considered for participation on this protocol.\n2. Infection with hepatitis B and active viral replication.\n3. Infection with hepatitis C and active viral replication.\n4. Patients currently being treated for bacterial, fungal or viral infection.\n5. Documented myocardial infarction within 6 months of study participation and\u002For symptomatic coronary artery or valvular disease or uncontrolled arrhythmia.\n6. Investigational drug use within 30 days before effusion collection.\n7. Cytotoxic anti-cancer or radiation therapy administration within 2 weeks of effusion collection. The exclusion does not apply to patients receiving monoclonal antibody therapy targeting immune checkpoint molecules.\n8. Corticosteroid therapy \\> 10 mg of prednisone (biological equivalent) daily within 2 weeks before effusion collection.\n9. Immunosuppressive therapy that cannot be stopped for 4 weeks prior to effusion collection as deemed by the prescribing physician.\n10. Laboratory abnormalities that indicate clinically significant hematological, hepatobiliary, or renal disease:\n\n    AST\u002FSGOT \\> 2.0 times the upper limit of normal ALT\u002FSGPT \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal, unless patient has Gilbert Syndrome (\\>3.0 times the upper limit of normal) Hemoglobin \\\u003C 8 gm\u002FdL or dependent upon transfusion to maintain ≥ 8 gm\u002FdL White blood cell count \\\u003C 2,000\u002Fmm3 Platelet count \\\u003C 100,000\u002Fmm3 or dependent upon transfusion to maintain ≥ 100,000 mm3 Creatinine \\> 2.0 times the upper limit of normal or calculated creatinine clearance ≤ 40 mL\u002Fmin.\n11. Pregnant or lactating females.\n12. Prior solid organ transplantation\n13. Patients who, in the opinion of the Investigator, will be non-compliant with study schedules or procedures.\n14. Patients who belong to a vulnerable population such as the homeless, the developmentally disabled and prisoners or have any condition that impairs their ability to provide informed consent or comply with study schedules or procedures.\n15. Patients with documented anaphylaxis as a result of penicillin allergy.","ALL","18 Years","79 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2). Based on previous research it is believed that it may help fight the tumor and relieve symptoms.\n\nAs a participant, their pleural fluid will be collected and the PIT cells will be isolated and expanded in the lab to create the ACT product. Before receiving the ACT product through their pleural catheter, they will undergo outpatient lymphodepleting chemotherapy. LDC is a standard procedure for many approved immunotherapy treatments Following the infusion, they'll receive IL-2 through the catheter for two days to stimulate the expanded PIT cells.\n\nThe active treatment phase lasts about three weeks, with follow-up visits over five years at AHN West Penn Hospital, potentially requiring a hospital stay of up to six days. Blood samples will be taken to monitor their response. As this is a first-in-human study, treatment carries an unknown risk up to and including death from toxicity. However, the risks of similar immunotherapy treatments are well documented.",[28,29,30,31],"Malignant Pleural Effusion","Malignant Mesothelioma","Pleural Effusion, Malignant","Metastasis to Pleura",[33,34,35,36,37,38,39,40],"metastasis to pleura","pleural infiltrating T cells","CliniMACS Prodigy","malignant mesothelioma","pleural effusion, malignant","Adoptive Cellular Therapeutic","immunotherapy","autologous tumor infiltrating lymphocytes (TIL)","RECRUITING","2026-04-01",{"date":44,"type":45},"2026-04-07","ACTUAL",{"date":47,"type":22},"2026-05",{"date":49,"type":22},"2038-03",{"name":51,"class":52},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":26,"conditions":64,"keywords":65,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":53},"100607772","phase-1-fast-tils-to-treat-metastatic-cancer-patients-with-pleural-disease-100607772","NCT07192900","Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease","Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease: A Phase I Trial","(RIOT 4A)","Inclusion Criteria:\n\n1. Patients with symptomatic, biopsy-proven malignant to the pleura, or mesothelioma with pleural effusions. Patients must have received and be refractory to available standard of care (SOC) therapy specific to their cancer type and must have exhausted or failed available standard of care with clinical benefit.\n2. Patients will be ≥ 18 and \\\u003C 80 years of age.\n3. Female patients of childbearing potential must have a negative urine or serum pregnancy test and if sexually active must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), an injectable contraceptive (such as Depo-Provera), or an oral contraceptive. Active contraception should continue for at least 6 months after ACT administration. Male participants must be willing to practice birth control from the time of enrollment on this study and for 6 months after receiving the preparative regimen.\n4. Cardiac ejection fraction ≥ 0.45 by Multiple-Gated Acquisition (MUGA) or echocardiography.\n5. No requirement for supplemental oxygen and no dyspnea immediately after effusion drainage.\n6. Karnofsky performance score ≥ 70.\n7. Patients must have an expected survival \\> 12 weeks.\n8. Patients must be able to comprehend the risks and methods used in this clinical trial and independently consent to participate.\n9. Patients must consent to collection of demographic and clinical data.\n\nExclusion Criteria:\n\n1. Patients with breast, kidney, lung, pancreatic, prostate, ovarian, rare cancers, and melanoma.\n2. Infection with Human Immunodeficiency Virus (HIV) and active viral replication. Patients with an undetectable viral load on Anti-retroviral Therapy (ART) can be considered for participation on this protocol.\n3. Infection with hepatitis B and active viral replication.\n4. Infection with hepatitis C and active viral replication.\n5. Patients currently being treated for bacterial, fungal or viral infection.\n6. Documented myocardial infarction within 6 months of study participation and\u002For symptomatic coronary artery or valvular disease or uncontrolled arrhythmia.\n7. Investigational drug use within 30 days before effusion collection.\n8. Cytotoxic anti-cancer or radiation therapy administration within 2 weeks of effusion collection. The exclusion does not apply to patients receiving monoclonal antibody therapy targeting immune checkpoint molecules.\n9. Corticosteroid therapy \\> 10 milligrams (mg) of prednisone (biological equivalent) daily within 2 weeks before effusion collection.\n10. Immunosuppressive therapy that cannot be stopped for 4 weeks prior to effusion collection as deemed by the prescribing physician.\n11. Laboratory abnormalities that indicate clinically significant hematological, hepatobiliary, or renal disease:\n\n    AST\u002FSGOT \\> 2.0 times the upper limit of normal ALT\u002FSGPT \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal, unless patient has Gilbert Syndrome (\\>3.0 times the upper limit of normal) Hemoglobin \\\u003C 8 gm\u002FdL or dependent upon transfusion to maintain ≥ 8 gm\u002FdL White blood cell count \\\u003C 2,000\u002Fmm3 Platelet count \\\u003C 100,000\u002Fmm3 or dependent upon transfusion to maintain ≥ 100,000 mm3 Creatinine \\> 2.0 times the upper limit of normal or calculated creatinine clearance ≤ 40 mL\u002Fmin.\n12. Pregnant or lactating females.\n13. Prior solid organ transplantation\n14. Patients who, in the opinion of the Investigator, will be non-compliant with study schedules or procedures.\n15. Patients who belong to a vulnerable population such as the homeless, the developmentally disabled and prisoners or have any condition that impairs their ability to provide informed consent or comply with study schedules or procedures.\n16. Patients with documented anaphylaxis as a result of penicillin allergy.",{"count":21,"type":22},[25],[28,29,30,31],[33,34,35,36,37,38,39,40],"2026-01-13",{"date":68,"type":45},"2026-01-15",{"date":70,"type":22},"2026-03",{"date":72,"type":22},"2037-12",{"name":74,"class":52},"David Bartlett, MD",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":53},"100605858","comparison-of-talc-slurry-versus-talc-insufflation-a-study-on-effectiveness-safety-and-hospital-outcomes-in-pleurodesis-100605858","NCT07167992","Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis","Inclusion Criteria:\n\n* patients aged 12 years and older.\n* Diagnosed with malignant pleural effusions or pneumothoraces.\n* ECOG performance status of 0-2.\n* Life expectancy of at least 3 months.\n* Ability to provide informed consent.\n* No contraindications to general anesthesia or conscious sedation.\n\nExclusion Criteria:\n\n* Patients younger than 12 years old\n* Female patients who are pregnant or lactating\n* Patients with encysted or septated pleural effusions and pneumothoraces\n* Patients presenting with respiratory failure\n* Patients complaining of dyspnea in spite of complete evacuation of pleural effusion or pneumothorax.\n* Patients with evident chest infection with clinical or laboratory signs suggestive of parapneumonic effusions.","12 Years",{"count":83,"type":22},160,[85],"NA","Pleural effusion is characterized by the accumulation of fluid in the pleural space, which typically contains about 10-20 mL of pleural fluid that is crucial for the movement of the lungs against the chest wall. This fluid closely resembles plasma but has a lower protein concentration, usually less than 1.5 gm\u002FdL. It primarily originates from pleural capillaries and the interstitial spaces of the lung, and is reabsorbed through the lymphatic vessels in the parietal pleura, either via small openings known as stomas or through a process called transcytosis (1, 2). When the balance between fluid production and reabsorption is disrupted-often due to various pathogenic mechanisms-it can lead to pleural effusion. In such cases, effective management is essential. This study aims to conduct a thorough comparison of the two talc administration methods-TS and TI-using sterilized, large-particle, asbestos-free talc powder. By examining key outcome measures such as pleurodesis success rates, procedural morbidity, and length of hospital stay, the goal is to provide clinicians with evidence-based guidance to facilitate informed decision-making in the management of pleural effusions.",[88,89,30,90],"Pneumothorax Spontaneous Primary","Pneumothorax Spontaneous Secondary","Pleurodesis",[92,93,90,94,95],"Talc slurry","Talc Insufflation","malignant pleural effusions","recurrent pneumothorax","NOT_YET_RECRUITING","2026-01-03",{"date":99,"type":45},"2026-01-06",{"date":101,"type":22},"2026-02-01",{"date":103,"type":22},"2027-03-30",{"name":105,"class":52},"University of Health Sciences Lahore",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":53},"100608965","pleurodesis-in-small-bore-chest-tube-100608965","NCT07208409","Pleurodesis in Small-bore Chest Tube","How Small Is Small - Pleurodesis in Small-Bore Chest Tube","Inclusion Criteria:\n\n* Pleural effusion.\n* With clinical indications for pleural drainage and chest drain insertion.\n* With anticipated need for pleurodesis e.g. known malignancy, no clinical signs of pleural infection.\n* age ≥18 year-old\n\nExclusion Criteria:\n\n* Pleural effusion not sizable for drainage.\n* With clinical suspicion of pleural infection e.g. pleuritic chest pain, fever, ultrasound showed loculated pleural effusion\n* Age ≤18 year-old",{"count":114,"type":22},60,[85],"Malignant pleural effusion (MPE) imposes a high burden on the healthcare system in the Asian Pacific region, as lung and breast cancer are the commonest cancers associated with malignant pleural effusion, as the two commonest cancers in the Asian Pacific region.\n\nWhile indwelling pleural catheter (IPC), a catheter that is inserted for long-term drainage of pleural fluid, is not commonly used in Asian countries, small-bore chest tubes are increasingly used due to their ease of insertion and causing less pain.\n\nInjecting talc, a chemocal, to promote adhesion of pleura, called talc pleurodesis was an effective method of managing MPE. However, the optimal size of small-bore chest tubes and the feasibility of talc pleurodesis have not been thoroughly investigated.\n\nThis randomised controlled trial aims to evaluate the feasibility and success rate of pleurodesis using small-bore chest drains and to examine the outcomes associated with different sizes of these drains, namely 8 Fr, 12 Fr, and 14 Fr, in managing MPE.\n\nThe primary outcome is the feasibility of talc pleurodesis with different small-bore chest tubes. Secondary outcomes include the differences in recurrence rates post-pleurodesis between small-bore and ultra-small-bore chest tubes, as well as patient outcomes such as pain scores, SpO2\u002FFiO2 ratios (oxygen saturation\u002Ffractional inspired oxygen ratio), and complications.\n\nThe sample size will be 60, and the project will be carried out over one year.\n\nThe outcome of this study can serve as a reference for managing MPE regarding the feasibility, safety, and efficacy of ultra-small-bore chest tubes worldwide, particularly in the Asia-Pacific region, where IPC is less common.",[30],[119,120,121],"malignant pleural effusion","pleurodesis","small bore chest tube","2025-12-17",{"date":124,"type":45},"2025-12-24",{"date":101,"type":22},{"date":127,"type":22},"2029-01-31",{"name":129,"class":52},"The University of Hong Kong",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":53},"100588829","first-local-anaesthesia-thoracoscopy-for-pleural-effusion-diagnosis-100588829","NCT06946498","First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.","Local Anesthesia Thoracoscopy as a First Line Approach in the Diagnosis of Suspected Malignant Pleural Effusion: FLAT Trial.","FLAT","Inclusion Criteria:\n\n* Undiagnosed pleural effusion with the character of a lymphocytic exudate\n\nExclusion Criteria:\n\n* Empyema\n* Transudate pleural effusion.\n* Central airway obstruction by tumor.\n* Existence of extensive adhesions that do not allow the development of iatrogenic pneumothorax and the safe entry of the thoracoscope.\n* Uncontrollable cough.\n* Acute respiratory failure and\u002For Hypercapnia.\n* Performance Status: 5","90 Years",{"count":140,"type":22},100,[85],"Non randomized study with two groups. The study group includes patients with suspected malignant pleural effusion, in whom the investigation of pleural effusion begins directly with pleural biopsy by Local Anesthesia Thoracoscopy (LAT).\n\nThe Control Group includes patients who come to the same hospital and are treated with the Standard of Care (SOC) strategies were used. Efficacy of LAT, Sensitivity, Hospitalization, time to diagnosis and general safety and comfort of the groups' subjects will be assessed.",[144,145,30,146],"Suspected Malignant Lung Neoplasm","Pleural Effusion","Mesothelioma, Malignant",[28,148,149,150,151,152],"Local Anesthesia Thoracoscopy","Medical Thoracoscopy","Lung cancer","Mesothelioma","Lymphocytic Exudate","2025-04-20",{"date":155,"type":45},"2025-04-27",{"date":157,"type":45},"2023-05-23",{"date":159,"type":22},"2026-12-31",{"name":161,"class":52},"National and Kapodistrian University of Athens",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":53},"100415041","early-phase-1-dual-targeting-her2-and-pd-l1-car-t-for-solid-tumors-100415041","NCT04684459","Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors","Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 for HER2-positive Solid Tumors","Inclusion Criteria:\n\n1. Male or female, Age 18-75 years old; If the subjects are over 75 years old, the researchers will determine whether to enroll according to the basic health conditions of the subjects, regardless of gender. No upper age limit was set for chest\u002Fabdominal reinfusion CAR-T subjects.\n2. Estimated life expectancy ≥ 3 months (according to investigator's judgement);\n3. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2;\n4. Patients diagnosed as ovarian cancer, non-small cell lung cancer, breast cancer, gastric cancer, head and neck cancer, pancreatic cancer, colorectal cancer, transitional cell carcinoma, endometrial carcinoma, sarcoma, glioblastoma, cholangiocarcinoma, etc. have received standard systemic treatment, have systemic metastasis\u002Fserosal cavity metastasis or are not tolerated;\n5. Expressing HER2 \\>20% of primary tumors or metastatic cells in the serous cavity by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH);\n6. Absolute neutrophil count ≥ 1×10\\^9\u002FL, platelet count ≥ 75×10\\^9\u002FL, absolute lymphocyte count ≥0.5×10\\^8\u002FL, hemoglobin ≥ 8.0 g\u002Fdl;\n7. Creatinine clearance rate ≥60ml\u002Fmin, Serum ALT\u002FAST≤2.5 times of the normal level, and total bilirubin≤1.5 times of the normal level;\n8. Cardiac ejection fraction ≥50%, no pericardial effusion;\n9. No other serious diseases (autoimmune diseases or any immune deficiency disease or other disease in need of immunosuppressive therapy);\n10. Patients must stop chemotherapy and targeted therapy for at least 3 weeks before starting treatment;\n11. Patients must take reliable contraceptive measures before entering the trial, during the research process until 1 year after CAR-T infusion; reliable contraceptive measures will be determined by the main investigator or designated personnel;\n12. Voluntarily participate in the research, understand and sign the informed consent;\n13. The side effect of the last anti-tumor treatment was reduced to ≤1 grade, except for hair loss.\n\nExclusion Criteria:\n\n1. Allergic to cytokines;\n2. Uncontrolled activity infection;\n3. Acute or chronic (graft-versus-host disease) GVHD;\n4. Accompanied by other uncontrolled malignant tumors;\n5. Patient with hepatitis B or C active period, HIV infection ≥ the upper limit of the normal level;\n6. Suffer from serious diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, etc.;\n7. Patients with grade 2-3 hypertension or poorly controlled;\n8. History of mental illness that is difficult to control;\n9. Patients have used immunosuppressive agents for a long time after organ transplantation, except for recent or current inhaled corticosteroid therapy;\n10. The existing medical history or mental state history or laboratory abnormalities may increase the risk associated with participating in the study or the administration of the study drug;\n11. Unstable pulmonary embolism, deep venous embolism or other major arterial\u002Fvenous thromboembolic events occurred within 6 months before enrollment. If receiving anticoagulant therapy;\n12. Pregnant or nursing women, or plan to become pregnant during the treatment period or within 1 year after the treatment ends;\n13. Patient suffering from diseases that have signed written informed consent or comply with research procedures; or are unwilling or unable to comply with research requirements.","75 Years",{"count":171,"type":22},18,[173],"EARLY_PHASE1","CAR-T therapy has achieved unprecedented success in hematological tumors in recent years, but the progress of CAR-T cells in the treatment of solid tumors is facing difficulties. HER-2 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors. In this study, the PD-L1 inhibitory signal was transformed into an activation signal in the tumor microenvironment, and enhanced the killing activity and survival ability of CAR-T cells. The HER-2\u002FPD-L1 dual-targeting CAR-T will be investigated in patients with HER2-positive solid tumors, and all enrolled subjects will receive HER2\u002FPD-L1 CAR T cells via intravenous or thoracic\u002Fperitoneal cavity infusion.",[176,30,177],"Peritoneal Carcinoma Metastatic","HER2 Positive Malignancies","2024-10-27",{"date":180,"type":45},"2024-10-30",{"date":182,"type":45},"2021-03-12",{"date":184,"type":22},"2025-12-30",{"name":186,"class":52},"Sichuan University",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100492560","cancer-ratiopleural-fluid-adenosine-deaminaselactate-dehydrogenase-interferony-tumor-necrosis-factorand-interleukins21218for-differentiation-between-malignant-and-non-malignant-pleural-effusion-100492560","NCT05693727","Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion","Inclusion Criteria:\n\n* Patients (100 cases) with exudative pleural effusion who will be admitted to Department of Chest diseases and Tuberculosis, Assiut University Hospital\n\nExclusion Criteria:\n\n* Age ˂ 18 years\n* Refusal to participate in the study",{"count":140,"type":22},"OBSERVATIONAL","To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion",[30],"2023-01-20",{"date":199,"type":45},"2023-01-23",{"date":201,"type":22},"2023-09-01",{"date":203,"type":22},"2027-09-01",{"name":205,"class":52},"Assiut University"]